The correlation analysis of miR-28+ib signature expression with clinical outcome in an R-CHOP-treated ABC-DLBCL cohort suggests that miR-28+ibrutinib combination therapy would benefit patients with any ABC-DLBCL genetic subtype. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.